Bicara Therapeutics 1Q26 Earnings Update

Bicara Therapeutics reported 1Q26 results highlighted by a cash runway extending to 2029 and updates on the Phase 3 FORTIFI-HN01 trial. Goldman Sachs raised the price target to $18 following model adjustments and clinical pipeline progress.

Key Takeaways

• 1.Bicara has a strong cash position of $539.8M, expected to fund operations into 1H29.
• 2.Management is initiating a bridging study in 3Q26 to evaluate a Q3W maintenance dose for ficerafusp alfa.
• 3.Phase 3 FORTIFI-HN01 trial enrollment is tracking for completion by YE26, enabling an interim analysis in mid-2027.

Table of Contents

• Longer follow-up data from the 1500mg QW, 750mg QW, and 200mg Q2W Phase 1b cohorts at ASCO
• Bridging study to show consistency b/w ficera's 2250mg Q3W and 1500mg QW doses
• Key updates in the next ~12 months:
• Model updates:
• Additional key takeaway
• Upcoming Events in the Next 12-18 Months
• Financial Statements and Model Changes
• Valuation and Risks
• Disclosure Appendix
• Price target and rating history chart(s)
• Target price history table(s)
• Regulatory disclosures

Document Preview

Page 1 of 5

Subscribe for full accessStart Free Trial